Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Roma - Area Ematologica
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Roma - Area Ematologica
Roma, Italy6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Registry-study of ELZONRIS in Participants With BPDCN | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-08-25 | NCT07785154 | |
| Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Not stated | 2026-06-09 | NCT04282811 | |
| Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY). | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, myeloproliferative neoplasm | Active, not recruiting | Not stated | 2025-09-23 | NCT04378855 | |
| Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) | High-risk MDS | Recruiting | Phase 3 | 2025-04-29 | NCT04184505 | |
| Study on the Diagnosis and Management of CLL in Italy by GIMEMA | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2025-03-14 | NCT04867915 | |
| Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2024-11-08 | NCT04168502 |